Invanz Related Published Studies
Well-designed clinical trials related to Invanz (Ertapenem)
Phase 2, randomized, double-blind study of the efficacy and safety of two dose
regimens of eravacycline versus ertapenem for adult community-acquired
complicated intra-abdominal infections. [2014]
Randomised clinical trial of moxifloxacin versus ertapenem in complicated
intra-abdominal infections: results of the PROMISE study. [2013]
A prospective, multi centre, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin-Sulbactam 3 days in the treatment of localized community acquired intra-abdominal infection. (T.E.A. Study: Three days Ertapenem vs three days Ampicillin-sulbactam). [2011.04.18]
Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. [2009.04]
Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. [2007.09]
Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. [2006.12.21]
Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. [2006.04]
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. [2005.11.12]
Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections. [2005.08]
Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. [2005.07]
Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. [2004.10]
Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. [2004.06]
Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam. [2004.06]
Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam. [2004.03]
Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam. [2004.02]
Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. [2004.01]
Ertapenem therapy for community-acquired pneumonia in the elderly. [2003.11]
[New Beta-lactam agent in the treatment of intra-abdominal sepsis: double blind and randomized stage III study of ertapenem versus piperacillin/tazobactam] [2003.07]
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. [2003.05]
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. [2003.02]
Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study. [2003]
A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. [2002.11]
Pharmacokinetics of ertapenem in healthy young volunteers. [2002.11]
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. [2002.09.01]
Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. [2002.09]
Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. [2002.09]
A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. [2002.07]
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. [2002.06.01]
A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. [2002.04.15]
Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone. [2002.03]
Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam. [2002.01]
Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections. [2002.01]
Well-designed clinical trials possibly related to Invanz (Ertapenem)
Prospective randomized trial comparing short-term antibiotic therapy versus standard therapy for acute uncomplicated sigmoid diverticulitis. [2010.06]
Definitive risk factors for anastomotic leaks in elective open colorectal resection. [2008.09]
Polyethylene glycol versus sodium phosphate mechanical bowel preparation in elective colorectal surgery. [2007.02]
Other research related to Invanz (Ertapenem)
Ertapenem prophylaxis of surgical site infections in elective colorectal surgery
in China: a multicentre, randomized, double-blind, active-controlled study. [2014]
Ertapenem versus ceftriaxone for the treatment of complicated infections: a
meta-analysis of randomized controlled trials. [2014]
Randomised clinical trial of moxifloxacin versus ertapenem in complicated
intra-abdominal infections: results of the PROMISE study. [2013]
T.E.A. Study: three-day ertapenem versus three-day Ampicillin-Sulbactam. [2013]
Penetration of ertapenem into muscle measured by in vivo microdialysis in mechanically ventilated patients. [2011.07]
Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa rates. [2011.06]
Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem. [2011.06]
Prophylaxis with ertapenem in patients with obstructive jaundice undergoing endoscopic retrograde cholangiopancreatography: safety, efficacy, and biliary penetration. [2011.03]
Central nervous system toxicity associated with ertapenem use. [2011.01]
A prospective, multi centre, randomized clinical study to compare the efficacy
and safety of Ertapenem 3 days versus Ampicillin-Sulbactam 3 days in the
treatment of localized community acquired intra-abdominal infection. (T.E.A.
Study: Three days Ertapenem vs three days Ampicillin-sulbactam). [2011]
Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes. [2010.12]
Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents. [2010.12]
Salvage therapy with tigecycline for recurrent infection caused by ertapenem-resistant extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. [2010.11]
Prevalence and characteristics of ertapenem-nonsusceptible Escherichia coli in a Taiwanese university hospital, 1999 to 2007. [2010.11]
Refractory vertebral osteomyelitis due to CTX-M-14-producing Escherichia coli at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen. [2010.09]
Decrease in serum valproic acid levels during treatment with ertapenem. [2010.08]
Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. [2010.07]
Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. [2010.05]
Ertapenem. [2010.03]
Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients. [2010.02]
Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. [2010.01]
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials. [2009.12.02]
Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. [2009.12]
Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population. [2009.11]
Ertapenem. [2009.10]
[Activity of Ertapenem and Ceftriaxone in the eradication of Salmonella in a model of experimental peritonitis in mice] [2009.09]
Detection of plasmid-mediated IMP-1 metallo-beta-lactamase and quinolone resistance determinants in an ertapenem-resistant Enterobacter cloacae isolate. [2009.05]
The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study. [2009.05]
Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. [2009.05]
Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates. [2009.04]
Ertapenem peritoneal fluid concentrations in adult surgical patients. [2009.04]
The use of ertapenem for the treatment of lower extremity infections. [2009.03]
Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. [2009.03]
Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection. [2009.02]
[Work of a multidisciplinary team in the control of the prescription of ertapenem] [2009.01]
Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. [2009.01]
Effect of early antibiotic prophylaxis with ertapenem and meropenem in experimental acute pancreatitis in rats. [2009]
The treatment of diabetic foot infections: focus on ertapenem. [2009]
Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. [2009]
Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem. [2009]
Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection. [2008.10.20]
Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative bacteraemia. [2008.10]
Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem. [2008.08]
Comparative costs of ertapenem and cefotetan as prophylaxis for elective colorectal surgery. [2008.06]
Ertapenem-induced acute pancreatitis in a surgical elderly patient. [2008.06]
Meta-analysis: ertapenem for complicated intra-abdominal infections. [2008.05]
Effect of Body Mass Index and Ertapenem versus Cefotetan Prophylaxis on Surgical Site Infection in Elective Colorectal Surgery. [2008.04]
[Septic shock due to community-acquired complicated intra-abdominal infection treated with ertapenem: outcome in 25 cases] [2008.04]
A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs >or=5 days in community-acquired intraabdominal infection. [2008.03]
Ertapenem for complicated intra-abdominal infections: a meta-analysis of randomized controlled trials. [2008.02.09]
Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report. [2008.02]
Efficacy of Ertapenem for Consolidation Therapy of Extended-Spectrum {beta}-lactamase-Producing Gram-Negative Infections: A Case Series Report (February). [2008.01.29]
Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency. [2008]
[In vitro activity of ertapenem against clinical bacterial isolates in 69 Spanish medical centers (E-test study)] [2007.12]
Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections. [2007.10]
Diffusion of ertapenem into bone and synovial tissues. [2007.10]
A Prospective, Double-Blind, Multicenter, Randomized Trial Comparing Ertapenem 3 Vs >/=5 Days in Community-Acquired Intraabdominal Infection. [2007.09.11]
Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid. [2007.09]
Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum {beta}-lactamase-producing organisms in an intensive care unit. [2007.08]
Antipneumococcal activity of ertapenem compared with gatifloxacin in a temperature-sensitive murine model of acute pneumonia. [2007.08]
Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. [2007.08]
Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy. [2007.08]
Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases. [2007.08]
Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan. [2007.07.17]
Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy. [2007.05.15]
Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections. [2007.05.15]
|